Adults with depression and who receive certain types of anti-depressants have an increased risk of developing Clostridium difficile, a costly and serious hospital-associated infection, according to a new University of Michigan Health System study.
[More]
Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted the Company's late-stage antibiotic candidate ceftolozane/tazobactam (CXA-201) Fast Track status in the previously granted Qualified Infectious Disease Product indications, Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia and Complicated Urinary Tract Infections.
[More]
A first-ever vaccine created by University of Guelph researchers for gut bacteria common in autistic children may also help control some autism symptoms.
[More]
ViroPharma Incorporated, an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs and rare diseases, today announced the results of a Phase 2 study of VP20621 (non-toxigenic Clostridium difficile; NTCD) a novel treatment approach for preventing recurrent C. difficile infections.
[More]
Older adults represent an important and growing demographic in emergency departments across the country, with urinary tract infections being one of the leading causes for ED visits.
[More]
A recent study funded by Centers for Disease Control and Prevention Epicenters Program and published in Infection Control and Hospital Epidemiology ( Deverick H. Anderson , M.D., MPH et al., 2013) supports and expands on previously published studies confirming the effectiveness of an automated UV-C-emitting device to combat the pathogens Clostridium difficile (C. diff.), vancomycin-resistant enterococci (VRE) and Acinetobacter spp. – some of the common culprits of health care-associated infections drawing increased attention for hospitals across the country.
[More]
Researchers have been able to reconstruct the genome sequence of an outbreak strain of Shiga-toxigenic Escherichia coli (STEC), which caused over 50 deaths in Germany, using an approach known as metagenomics which bypasses the need for growing bacteria in the lab.
[More]
Researchers have been able to reconstruct the genome sequence of an outbreak strain of Shiga-toxigenic Escherichia coli using metagenomics (the direct sequencing of DNA extracted from microbiologically complex samples), according to a study in the April 10 issue of JAMA, a Genomics theme issue.
[More]
With rates and deaths associated with Clostridium difficile (C. difficile) at historically high levels, many hospitals have taken extra steps to reduce these infections. New research finds that a dedicated daily cleaning crew who adequately clean and disinfect rooms contaminated by C. difficile using a standardized process can be more effective than other disinfection interventions.
[More]
Treating patients with cells may one day become as common as it is now to treat the sick with drugs made from engineered proteins, antibodies or smaller chemicals, according to UC San Francisco researchers.
[More]
Patients receiving antihistamines to suppress stomach acid are at greater risk of infection from Clostridium difficile, or C. diff, a common cause of diarrhea, particularly in health care settings, Mayo Clinic researchers have found.
[More]
In an effort to stop the transmission of Clostridium difficile infections, which claim the lives of at least 14,000 Americans annually, the Association for Professionals in Infection Control and Epidemiology has issued an updated Implementation Guide to help clinicians protect patients.
[More]
Patients with a left-sided brain injury are more likely to develop hospital-acquired infections than those with right-sided injury, show study findings.
[More]
Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated the company's late-stage antibiotic candidate, ceftolozane/tazobactam, as a Qualified Infectious Disease Product (QIDP) for the indications of Hospital-Acquired Bacterial Pneumonia (HABP)/Ventilator-Associated Bacterial Pneumonia (VABP) and Complicated Urinary Tract Infections (cUTI).
[More]
Clostridium difficile infections have developed into a virtual pandemic over the past two decades. The outcome of standard antibiotic treatment is unsatisfactory: the recurrence rates are high with every relapse increasing the risk of further follow-ups. Faecal microbiota transplantation offers a rapidly acting and highly effective alternative in treating recurrent Clostridium difficile infections (RCDI), as Professor Lawrence J. Brandt (Montefiore Medical Center, New York, USA) points out.
[More]
Hospitals in the U.S. continue to make progress in the fight against central line-associated bloodstream infections and some surgical site infections, according to a report issued today by the Centers for Disease Control and Prevention (CDC). Catheter-associated urinary tract infections remained unchanged between 2010 and 2011.
[More]
Australian biopharmaceutical company Specialised Therapeutics Australia announces that a phase III clinical trial of world leading breast cancer drug ABRAXANE (nanoparticle albumin-bound paclitaxel) in combination with current standard of care gemcitabine in patients with advanced pancreatic cancer has demonstrated substantially improved survival times, with double the number of patients surviving two years.
[More]
Treatment of recurrent Clostridium difficile infection with donor feces infusion is significantly more effective than conventional vancomycin therapy, show results published in The New England Journal of Medicine.
[More]
Researchers have developed a risk-scoring system to identify noncritically ill hospital patients most likely to benefit from prophylactic acid-suppressive medication.
[More]
The impact of antibiotic misuse has far-reaching consequences in healthcare, including reduced efficacy of the drugs, increased prevalence of drug-resistant organisms, and increased risk of deadly infections. A new study featured in the February issue of Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America, found that many patients with Clostridium difficile infection (C. difficile) are prescribed unnecessary antibiotics, increasing their risk of recurrence of the deadly infection.
[More]